Polycystic Ovarian Syndrome Treatment Market Manufacturers 2020 Growth Analysis, Technology Advancements, Segments Overview, Latest Trends, Regions and Major Driving Forces Till 2027
SEATTLE, March 25, 2021, (PHARMIWEB) — Polycystic ovary syndrome is a reproductive disorder that occurs during the reproductive age of females. PCOD is characterized by the irregular menstrual cycle, heavy bleeding, pain during menses, and abnormal hair growth on face due to the secretion of the excess male hormone. In this condition, the ovary develops numerous small follicles and fails to release an egg regularly. The factors driving polycystic ovarian syndrome treatment market are increasing funds and grants for research for novel treatment, increasing product approval and pipeline candidates, disease prevalence and high prevalence of risk-prone population.
Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/1589
Market – Driver
The organic and inorganic strategies adopted by the market players will boost the growth of the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of the polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.). The acquisition will expand Astellas’ clinical pipeline with fezolinetant, oral compound for the NK3 receptor target. Fezolinetant was in phase IIa clinical trials for the treatment of menopausal hot flashes, polycystic ovary syndrome (PCOS) and uterine fibroids. Moreover, product approval by various approval bodies will expand the treatment option and in turn leading to market growth. For instance, in 2014, EffRx Pharmaceuticals SA got US FDA approval for its proprietary metformin-based product candidate, EX404, for pediatric polycystic ovary syndrome (PCOS).
Growing funding for research and development of novel treatment will also foster the growth of the polycystic ovarian syndrome treatment market during the forecast period. For instance, in 2017, Bayer and the Society for Reproductive Investigation (SRI) launched the SRI-Bayer Discovery and Innovation Grants Program for supporting research initiatives for addressing unmet medical needs in women’s health. The grant is dedicated to research in endometriosis, uterine fibroids, and polycystic ovarian syndrome. Further, grants for the treatment of polycystic ovarian syndrome will fuel market growth. For instance, in 2017, as part of a multi-year endowment from PCOS Diva, the nonprofit organization PCOS Challenge, Inc. will be offering grants up to $500 to help women and girls struggling with hair and skin issues related to polycystic ovary syndrome (PCOS).
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now this Premium Report to Grow your Business @ https://bit.ly/3cjuBoA
The growing incidence of polycystic ovarian syndrome is projected to be a major driver for the polycystic ovarian syndrome treatment market growth. For instance, according to an article published in 2014 of Clinical Epidemiology, the polycystic ovarian syndrome affects 8 – 20 % of the reproductive-age women, globally. According to the World Health Organization, in the year 2012, the estimated number of the polycystic ovarian syndrome is 116 million worldwide.
Moreover, the growing prevalence of insulin resistance (IR), type 2 diabetes, obesity, and cardiovascular disease will further fuel the growth of the polycystic ovarian syndrome market. According to an article published in Lancet, globally, prevalence of overweight and obesity combined has risen by 27.5% for adults between 1980 and 2013. Moreover, according to data by the National Health and Nutrition Examination Survey (NHANES), 2013–2014, in the United States the percentage of obesity is higher in women, i.e. 40 %, than in men, 35%.
Market – Restraint
On the other side, off-labeled and generic drugs present in the market are expected to hamper the market growth. Moreover, the market is also hindered by the alternated treatment such as the used of surgical procedures such as ovarian drilling and laparoscopic drilling.
Regional Analysis
Regional segmentation of polycystic ovarian syndrome treatment market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America market is expected to emerge as the dominant market for polycystic ovary syndrome treatment market and this can be attributed to a high diagnosis rate, presence of a larger number of local players such as AstraZeneca, Teva, etc. and growing prevalence of the polycystic ovarian syndrome in the region.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/polycystic-ovary-syndrome-treatment-market-3425
Market – Competitor
The key player involved in the polycystic ovarian syndrome treatment market is Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Teva Pharmaceutical Industries Ltd., Eisai Pharmaceuticals India Pvt. Ltd (EIL), VIVUS, Inc., SkinMedica, Inc. (part of Allergan, Inc.), Ferring Pharmaceuticals Inc., AstraZeneca plc and EffRx, Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Regulatory Scenario
- PEST Analysis
- COVID-19 Impact Analysis
- Market Dynamics
- Global Polycystic Ovary Syndrome Treatment Market, By Drug Class, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Oral contraceptives
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Insulin Sensitizing Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Anti-Depressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Ornithine Decarboxylase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Aromatase Inhibitors & SERMs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Segment Trends
- Introduction
- Global Polycystic Ovary Syndrome Treatment Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global Polycystic Ovary Syndrome Treatment Market, By Regions, 2019 – 2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- North Africa
- Central Africa
- South Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
